Last €30.88 EUR
Change Today +0.005 / 0.02%
Volume 552.5K
As of 1:55 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (SAZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/31/13 - €42.50
52 Week Low
04/15/14 - €27.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STADA ARZNEIMITTEL AG (SAZ)

Related News

No related news articles were found.

stada arzneimittel ag (SAZ) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (SAZ) Details

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment offers non-prescription products, such as Grippostad and Ladival. This segment’s products also comprise Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,076 Employees
Last Reported Date: 04/30/14
Founded in 1895

stada arzneimittel ag (SAZ) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel ag (SAZ) Key Developments

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM

STADA AG Presents at 2014 Russian Pharmaceutical Forum, Jun-17-2014 02:55 PM. Venue: Corinthia Saint-Petersburu Hotel, 57 Nevskij Prospect, St. Petersburg, Russia. Speakers: Dmitriy Efimov, Senior Vice President for Russia, CIS and South East Europe.

Stada-Arzneimittel AG Approves Dividend for 2013

Stada-Arzneimittel AG announced that at the AGM held on June 4, 2014, the shareholders approved dividend of EUR 0.66 per common share, which is significantly higher than the previous year by 32%, with the remaining surplus being carried forward.

Stada-Arzneimittel AG Reports Earnings Results for the First Quarter Ended March 31, 2014; Confirms Outlook for Financial Year 2014

Stada-Arzneimittel AG reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported group sales of EUR 507.4 million against EUR 473.2 million for the same period last year. Operating profit was EUR 63.1 million against EUR 70.0 million for the same period last year. Adjusted operating profit was EUR 87.6 million against EUR 71.9 million for the same period last year. EBITDA was EUR 97.7 million against EUR 96.6 million for the same period last year. Adjusted EBITDA was EUR 114.7 million against EUR 98.2 million for the same period last year. Net income was EUR 35.0 million or EUR 0.58 earning per share against EUR 34.9 million or EUR 0.59 per share for the same period last year. Adjusted net income was EUR 52.6 million or EUR 0.87 per share adjusted against EUR 36.7 million or EUR 0.62 per share adjusted for the same period last year. The company confirmed outlook for financial year 2014. For the year, the company expects slight growth in group sales, adjusted EBITDA and adjusted net income.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €30.88 EUR +0.005

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 607.00 GBp +1.00
Richter Gedeon Nyrt 3,909 +59.00
Oxford Biomedica PLC 2.93 GBp 0.00
Skyepharma PLC 234.00 GBp -10.00
Vernalis PLC 32.25 GBp -0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation SAZ Industry Range
Price/Earnings 15.1x
Price/Sales 0.9x
Price/Book 1.9x
Price/Cash Flow 15.0x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at